Article
Oncology
A. Le Cesne, C. Chevreau, C. Perrin, A. Italiano, A. Hervieu, J. Y. Blay, S. Piperno-Neumann, E. Saada-Bouzid, F. Bertucci, N. Firmin, E. Kalbacher, B. Narciso, C. Schiffler, S. Yara, M. Jimenez, C. Bouvier, V. Vidal, S. Chabaud, F. Duffaud
Summary: The REGOBONE multicohort study investigated the efficacy and safety of regorafenib in patients with advanced bone sarcomas. This report focuses on patients with relapsed advanced or metastatic chordoma. The study found no significant benefit of regorafenib in patients with recurrent chordoma.
Article
Medicine, General & Internal
Rui-Tao Wang, Yang Zhao, An-Lei Wang, Yu-Ting Wang, Zhong-Ping Yin, Kai Chen
Summary: The study aimed to investigate the efficacy and safety of regorafenib in Chinese patients with previously treated metastatic colorectal cancer. Results showed potential clinical benefit of regorafenib monotherapy for patients who had failed standard chemotherapy regimens. Additionally, hypertension and hand-foot syndrome induced by regorafenib therapy could serve as valuable biomarkers to predict the prognosis of regorafenib treatment.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Oncology
Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, Jay Morris, Qianqian Liu, Jenny A. Mendez, Tyler Curiel, Joel Michalek, Devalingam Mahalingam
Summary: This study compared the efficacy of VOR/HCQ and RGF in mCRC, showing that VOR/HCQ had a shorter median progression-free survival but no significant difference in median overall survival compared to RGF. Both treatments were tolerated by patients and showed improved anti-tumor immunity in mCRC.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Florence Duffaud, Antoine Italiano, Emannuelle Bompas, Maria Rios, Nicolas Penel, Olivier Mir, Sophie Piperno-Neumann, Christine Chevreau, Corinne Delcambre, Francois Bertucci, Pascaline Boudou-Rouquette, Mathilde Cancel, Christophe Perrin, Esma Saada-Bouzid, Laure Monard, Camille Schiffler, Loic Chaigneau, Alice Hervieu, Olivier Collard, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud, Jean-Yves Blay
Summary: This multi-cohort trial investigated the efficacy and safety of regorafenib for advanced sarcomas of bone origin, focusing on patients with metastatic or locally advanced chondrosarcoma progressing after prior chemotherapy. While the primary endpoint was not statistically met in this small randomized cohort, there is modest evidence suggesting that regorafenib may slow disease progression in patients with metastatic CS after prior chemotherapy failure.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Richard F. Riedel, Silvia Stacchiotti, Elizabeth T. Loggers, Kristen N. Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia Del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F. Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K. Schwartz, James L. Chen, Hari Deshpande, Elizabeth J. Davis, Garth Nicholas, Stefan Groeschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herraez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A. Van Tine, Katharina Gotze, Filomena Mazzeo, Alexander Yakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A. Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R. Van Domelen, Christopher J. Walker, Hua Chang, Yosef Landesman, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Steven Attia
Summary: The clinical benefit of Selinexor in patients with advanced DD-LPS has been evaluated. The results showed that Selinexor improved PFS and time to next treatment compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Florence Duffaud, Jean-Yves Blay, Axel Le Cesne, Christine Chevreau, Pascaline Boudou-Rouquette, Elsa Kalbacher, Nicolas Penel, Christophe Perrin, Valerie Laurence, Emmanuelle Bompas, Esma Saada-Bouzid, Corinne Delcambre, Francois Bertucci, Mathilde Cancel, Camille Schiffler, Laure Monard, Corinne Bouvier, Vincent Vidal, Nathalie Gaspar, Sylvie Chabaud
Summary: Although the primary endpoint was not met statistically in this randomised cohort, there is evidence to suggest that regorafenib might modestly delay tumour progression in relapsed ES after failure of prior chemotherapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Dingwei Ye, Jiyan Liu, Aiping Zhou, Qing Zou, Hanzhong Li, Cheng Fu, Hailong Hu, Jian Huang, Shaoxing Zhu, Jie Jin, Lulin Ma, Jianming Guo, Jun Xiao, Se Hoon Park, Dahong Zhang, Xiusong Qiu, Yuanyuan Bao, Lilin Zhang, Wei Shen, Feng Bi
Summary: Tislelizumab showed meaningful clinical benefits in patients with previously treated PD-L1-positive urothelial carcinoma, with a 24% objective response rate and a durable response rate of 68%. The most common adverse events were anemia and pyrexia.
Article
Oncology
Guillem Argiles, Nuria Mulet, Manuel Valladares-Ayerbes, Jose M. Vieitez, Cristina Gravalos, Pilar Garcia-Alfonso, Cristina Santos, Maria Tobena, Beatriz Garcia-Paredes, Manuel Benavides, Maria T. Cano, Fotios Loupakis, Mercedes Rodriguez-Garrote, Fernando Rivera, Richard M. Goldberg, Chiara Cremolini, Jaafar Bennouna, Fortunato Ciardiello, Josep M. Tabernero, Enrique Aranda, Josep Tabernero
Summary: The safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients was evaluated. The alternative dosing schedules were found to be feasible and safe, with a greater improvement in adverse events observed in the intermittent dosing arm.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Yihebali Chi, Yongqian Shu, Yi Ba, Yuxian Bai, Baoli Qin, Xiuwen Wang, Jianping Xiong, Nong Xu, Helong Zhang, Jianfeng Zhou, Jianming Xu, Ying Cheng, Jifeng Feng, Chunhong Hu, Yigui Chen, Zhendong Chen, Jufeng Wang, Chengxue Dang, Jianhong Wang, Yiye Wan, Yong Tang, Donglin Wang, Jiang Liu, Minhui Wu, Yanhong Deng, Xingwen Li, Yongqiang Li, Jian Dong, Da Jiang, Guisheng Li, Qiong Wu, Jin Li, Yujuan Qi, Yongkun Sun, Jianqiang Cai
Summary: In summary, the study showed that treatment with Anlotinib significantly prolonged progression-free survival in patients with refractory metastatic colorectal cancer, with improvements in objective response rate and disease control rate. However, overall survival was similar between the two groups.
Article
Oncology
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, Akihito Kawazoe, Yasutoshi Kuboki, Kohei Shitara, Takashi Kojima, Hiroya Taniguchi, Jun Watanabe, Itaru Endo, Takayuki Yoshino
Summary: The study demonstrated that patients treated with TAS102 plus BEV had longer overall survival and progression-free survival compared to those treated with TAS102 or regorafenib monotherapy. TAS102 plus BEV was independently associated with better OS and PFS on multivariate analysis, with no unexpected adverse events observed in any group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Xin Wang, Ying Wang, Xiaolan Yong, Bojun Wu, Zilin Sun, Ning Lou, Qing Wen, Yufang Zhang, Shiyun Li, Jiarui Li, Yan He, Jinluo Cheng, Xiangdong Zhong, Jing Shen, Wenying Yang
Summary: The xanthine dipeptidyl peptidase-4 inhibitor, yogliptin, demonstrated effective hypoglycemic activity as a monotherapy in individuals with type 2 diabetes mellitus. It significantly reduced HbA1c levels and improved secondary efficacy outcomes, such as fasting plasma glucose levels, in Chinese T2DM patients. The safety profile of yogliptin was found to be favorable, supporting its use in phase III clinical studies.
JOURNAL OF DIABETES
(2022)
Article
Endocrinology & Metabolism
Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin, Kohjiro Ueki
Summary: The study demonstrated that imeglimin significantly improved HbA(1c) levels in Japanese patients with type 2 diabetes compared to placebo, and had a similar safety profile to placebo. Imeglimin represents a potential new treatment option for this population.
Article
Oncology
Jing Huang, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Yan Song, Jie He
Summary: A randomized trial in Chinese hospitals showed that anlotinib significantly improved progression-free survival in patients with advanced ESCC who had previously undergone chemotherapy, with common adverse events including hypertension, decreased appetite, and hyponatremia. This study suggests that antiangiogenic therapy could be an important therapeutic target for advanced ESCC.
Article
Oncology
Yue Ma, Jiting Zhou, Yuxin Ye, Xintian Wang, Aixia Ma, Hongchao Li
Summary: The cost-effectiveness of serplulimab versus regorafenib in previously treated unresectable or metastatic microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colorectal cancer in China was investigated. The results showed that, compared to regorafenib, serplulimab is a cost-effective treatment for patients with previously treated unresectable or metastatic MSI-H/dMMR colorectal cancer in China.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto Sobrero, James Yao, Pilar Garcia-Alfonso, Judit Kocsis, Antonio Cubillo Gracian, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csoszi, Chiara Cremolini, Francois Ghiringhelli, Ardaman Shergill, Howard S. Hochster, John Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng
Summary: This study evaluated the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of VEGFRs 1, 2, and 3, in patients with advanced, chemotherapy-refractory colorectal cancer. The results showed that fruquintinib significantly prolonged overall survival compared to placebo in patients with refractory metastatic colorectal cancer, with clinical significance. Therefore, fruquintinib could become a global treatment option for patients with refractory metastatic colorectal cancer.
